H.C. Wainwright’s Ed Arce reduces his price target on TTPH stock, anticipating the company’s UTI program has met its end.
Did an iceberg just wallop into Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock? This biotech company’s shares …
After Roche released initially reassuring datasets for its wet AMD and DME candidate, BTIG’s Dane Leone believes this spells trouble for REGN.
FBR’s George Zavoico looks ahead to CBIO’s next pivotal trial, bullish on CB 269d’s ability to lead to stable FIX activity into the mild hemophilia range.
H.C. Wainwright’s Joseph Pantginis serves up an upbeat take on a platform that is the fuel of all of PIRS’s current and future pipeline candidates.
BTIG’s Tim Chiang is out with a bearish case against Teva after last week’s less-than-stellar 2018 guidance reveal.
As Wall Street scrambles away from Teva after a sharp guidance miss for 2018, Oppenheimer’s Derek Archila shares his two (cautious) cents.
Gilead Sciences, Inc. (NASDAQ:GILD), which built its reputation on turning HIV drug cocktails into easy-to-use, daily, …